Biospace news

Alzheon Announces Appointment of Renowned Biopharma Executive Gino Santini to Board of Directors. 6/12/2024. Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients...
Trends
Sana Downsizes Staff by 29%, Refocuses on Ex Vivo Cell Therapy Platform. 10/11/2023. The biotech is laying off about 29% of its employees and will focus its resources on the company's hypoimmune platform. The latest downsizing follows a previous round...
Hematology/Oncology: AOP Health's Expanding Clinical Research Program Delivers New Results. 6/10/2024. AOP Orphan Pharmaceuticals GmbH continues a successful clinical research program in hematology/oncology with two abstracts accepted for presentation...
NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American. 6/7/2024. NovaBay® Pharmaceuticals, Inc. announces that the NYSE American LLC has accepted the Company's plan to regain compliance with NYSE American's continued listing standards.
WARREN, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell...
Sana Downsizes Staff by 29%, Refocuses on Ex Vivo Cell Therapy Platform. 10/11/2023. The biotech is laying off about 29% of its employees and will focus its resources on the company's hypoimmune platform. The latest downsizing follows a previous...
6/10/2024. Biophytis SA, a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, announces that it has submitted an Investigational New Drug application with the U.S. Food and Drug Administration...
BioSpace is proud to present its NextGen Bio Class of 2024, a list of the hottest new life sciences companies in the United States. To come up with this list, BioSpace identified companies that launched between September 2022 and September 2023 with...
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis. 6/11/2024. 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company" or "60 Degrees...
Published: Jun 12, 2024. LA JOLLA, Calif.-- ( BUSINESS WIRE )-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it...
See more